Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medifast (MED) Cost of Revenue (2016 - 2025)

Medifast (MED) has disclosed Cost of Revenue for 16 consecutive years, with $23.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 25.43% year-over-year to $23.0 million, compared with a TTM value of $110.6 million through Dec 2025, down 29.93%, and an annual FY2025 reading of $110.6 million, down 29.93% over the prior year.
  • Cost of Revenue was $23.0 million for Q4 2025 at Medifast, down from $27.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $131.7 million in Q2 2022 and bottomed at $23.0 million in Q4 2025.
  • Average Cost of Revenue over 5 years is $71.1 million, with a median of $72.0 million recorded in 2023.
  • The sharpest move saw Cost of Revenue surged 113.14% in 2021, then tumbled 53.75% in 2024.
  • Year by year, Cost of Revenue stood at $99.5 million in 2021, then grew by 4.12% to $103.6 million in 2022, then tumbled by 52.1% to $49.6 million in 2023, then plummeted by 37.99% to $30.8 million in 2024, then dropped by 25.43% to $23.0 million in 2025.
  • Business Quant data shows Cost of Revenue for MED at $23.0 million in Q4 2025, $27.2 million in Q3 2025, and $28.9 million in Q2 2025.